KROS - Keros Therapeutics, Inc.
NEXT EARNINGS:
Apr 30, 2026
(in 25 days)
EPS Est: $-1.03
|
Rev Est: $1.7M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$102.60
DETAILS
HIGH:
$107.00
LOW:
$96.00
MEDIAN:
$105.00
CONSENSUS:
$102.60
UPSIDE:
755.00%
Market Cap:
446.66M
Volume:
547,813
Avg Volume:
421,729
52 Week Range:
9.12-22.55
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.99
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
163
IPO Date:
2020-04-08
EPS (TTM):
1.86
P/E Ratio:
6.45
Revenue (TTM):
244.06M
Total Assets:
338.02M
Total Debt:
16.88M
Cash & Equiv:
287.42M
Rev Growth (5Y):
57.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
48.0%
ROCE (5Y avg):
-22.6%
ROE (5Y avg):
-22.4%
Debt/Equity:
0.06
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-03-04 | $-0.86 | $-0.49 | -75.5% | $385000 | $3.7M | -89.5% |
| 2025-11-05 | $-0.18 | $-1.11 | +83.8% | $14.3M | $3.7M | +289.4% |
| 2025-08-06 | $-0.76 | $-1.14 | +33.3% | $18.2M | $3.2M | +465.9% |
| 2025-05-06 | $3.62 | $-0.01 | +36300.0% | $211.2M | $56.6M | +272.9% |
| 2025-02-26 | $-1.14 | $-1.36 | +16.2% | $3.0M | $22.2M | -86.3% |
| 2024-11-06 | $-1.41 | $-1.26 | -11.9% | $388000 | $2.3M | -83.2% |
| 2024-08-07 | $-1.25 | $-1.23 | -1.6% | $37000 | — | — |
| 2024-05-08 | $-1.21 | $-1.31 | +7.6% | $83000 | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244.06M | 3.55M | 151,000 | 0 | 20.10M | 0 | 10.00M | 10.00M |
| Net Income | 87.01M | (187.35M) | (152.99M) | (104.68M) | (58.74M) | (45.36M) | (12.34M) | (1.33M) |
| EPS | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Total Assets | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M | 269.44M | 10.96M | 27.41M |
| Total Debt | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M | 899,000 | 1.27M | 788,000 |
| Cash & Equivalents | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M | 265.88M | 7.02M | 23.26M |
| Operating Cash Flow | 107.50M | (160.87M) | (124.51M) | (70.06M) | (62.15M) | (36.89M) | (16.00M) | 7.04M |
| Free Cash Flow | 105.95M | (162.80M) | (126.97M) | (71.30M) | (63.17M) | (37.19M) | (16.27M) | 6.83M |
| FCF per Share | 2.85 | -4.35 | -4.31 | -2.82 | -2.71 | -2.40 | -1.83 | 0.77 |
| Book Value | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M | 261.72M | 495,000 | 12.76M |
| Cash & ST Investments | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M | 265.88M | 7.02M | 23.26M |
| Return on Equity | 0.29 | -0.33 | -0.46 | -0.38 | -0.24 | -0.17 | -24.94 | -0.10 |
| Return on Capital Employed | 0.22 | -0.32 | -0.44 | -0.36 | -0.23 | -0.17 | -1.91 | -0.08 |